Design, synthesis, and characterization of novel, nonquaternary reactivators of GF-inhibited human acetylcholinesterase. 2014

Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
Southwest Research Institute, Chemistry and Chemical Engineering Division, Department of Medicinal and Process Chemistry, 6220 Culebra Road, San Antonio, TX 78266, USA. Electronic address: stanton.mchardy@utsa.edu.

The goal of this research was to identify structurally novel, non-quaternarypyridinium reactivators of GF (cyclosarin)-inhibited hAChE that possess the capacity to mediate in vitro reactivation of GF-inhibited human acetylcholinesterase (hAChE). New compounds were designed, synthesized and assessed in GF-inhibited hAChE assays. Structure activity relationships for AChE binding and reactivation of GF-inhibited hAChE were developed. Lead compounds from two different chemical series, represented by compounds 17 and 38, displayed proficient in vitro reactivation of GF-inhibited hAChE, while also possessing low inhibition of native enzyme.

UI MeSH Term Description Entries
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
March 2016, Toxicology letters,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
July 2020, Bioorganic chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
December 2018, Bioorganic chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
January 2012, Journal of medicinal chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
August 2017, Bioorganic & medicinal chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
October 1981, Journal of medicinal chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
September 2018, Journal of medicinal chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
March 2009, European journal of medicinal chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
May 2014, European journal of medicinal chemistry,
Stanton F McHardy, and Jonathan A Bohmann, and Michael R Corbett, and Bismarck Campos, and Michael W Tidwell, and Paul Marty Thompson, and Chris J Bemben, and Tony A Menchaca, and Tony E Reeves, and William R Cantrell, and William E Bauta, and Ambrosio Lopez, and Donald M Maxwell, and Karen M Brecht, and Richard E Sweeney, and John McDonough
June 2005, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!